Clinical trials · Michigan
Peripheral T Cell Lymphoma clinical trials in Michigan
We’re tracking 19 recruiting peripheral t cell lymphoma studies with a site in Michigan — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Grand Rapids, MichiganAges 1–31 - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Detroit, MichiganAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Kalamazoo, MichiganAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Ann Arbor, MichiganAges 18 years+ - NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Ann Arbor, MichiganAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Detroit, MichiganAges 18–75 - NCT03523975RecruitingPhase 1/Phase 2
Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Ann Arbor, MichiganAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Ann Arbor, MichiganAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Detroit, MichiganAges 18 years+ - NCT05079282RecruitingPhase 1
Study drug for relapsed or treatment-resistant T-cell lymphoma
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
Detroit, MichiganAges 18 years+ - NCT06393738RecruitingPhase 1
Study of ARV-393 for advanced non-Hodgkin lymphoma
This trial tests an experimental drug called ARV-393 for people with non-Hodgkin lymphoma that has come back or stopped responding to at least two previous treatments. The study aims to find out if the drug is safe and how well it works.
Detroit, MichiganAges 18 years+ - NCT06072131RecruitingPhase 3
Comparing belinostat or pralatrexate with chemotherapy for PTCL
This trial tests whether adding belinostat or pralatrexate to standard chemotherapy (CHOP) works better than CHOP alone for people newly diagnosed with peripheral T-cell lymphoma (PTCL). It aims to find a more effective first treatment option.
Detroit, MichiganAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Grand Rapids, MichiganAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Grand Rapids, MichiganAges 6 months–25 years - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Grand Rapids, MichiganAges 18 years+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Detroit, MichiganAges 18 years+ - NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Kalamazoo, MichiganAges 12 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Detroit, MichiganAges 18–66 - NCT06615050RecruitingPhase 3
Comparing two drug combinations for stem cell transplant
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
Detroit, MichiganAges 18 years+
Where these studies are running in Michigan
Institutions with a site for the recruiting peripheral t cell lymphoma studies listed above.
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · 7 studies
- University of Michigan · 6 studies
- Wayne State University/Karmanos Cancer Institute · 6 studies
- Henry Ford Health · 4 studies
- Weisberg Cancer Treatment Center · 3 studies
- Barbara Ann Karmanos Cancer Institute · 2 studies
- Beacon Kalamazoo · 2 studies
- Bronson Battle Creek · 2 studies
What taking part in a peripheral t cell lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Peripheral T Cell Lymphoma trials in other states
Common questions
- Are there peripheral t cell lymphoma clinical trials in Michigan?
- Yes. We're currently tracking 19 recruiting peripheral t cell lymphoma studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a peripheral t cell lymphoma study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New peripheral t cell lymphoma studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.